NCT06675136View on ClinicalTrials.gov

Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 17, 2025

Primary Completion Date

January 14, 2029

Study Completion Date

January 14, 2029

Conditions
Clinical Stage IVB Gastric Cancer AJCC v8Metastatic Gastric AdenocarcinomaMetastatic Malignant Neoplasm in the Peritoneum
Interventions
PROCEDURE

Biopsy

Undergo tumor biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

OTHER

Medical Device Usage and Evaluation

Given PIPAC

DRUG

Nab-paclitaxel

Given IP

DRUG

Paclitaxel

Given IV

OTHER

Questionnaire Administration

Ancillary studies

BIOLOGICAL

Ramucirumab

Given IV

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT06675136 - Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases | Biotech Hunter | Biotech Hunter